BFlow, we believe that groundbreaking science reaches its full potential only when it is supported by aligned investment and strategic partnerships. It is essential to bridge the gap between research and capital in order to transform innovation into real solutions.

Last week, we participated in the #InvertirenCienciaSÍesRentable forum, an initiative promoted by Unirisco and XesGalicia. The event created a valuable space where scientific innovation and investment communities could engage in meaningful dialogue around opportunity, scalability, and impact.

Showcasing Organ-on-a-Chip Technology

During the event, we presented our Organ-on-a-Chip platform, a cutting-edge technology designed to improve the predictive power of preclinical models and accelerate biomedical innovation.

Our platform stands out for:

  • High physiological relevance: replicating key aspects of human tissue microenvironments, including dynamic flow conditions and cellular interactions.
  • Risk and cost reduction in R&D: enabling earlier detection of efficacy and toxicity signals to support better decision-making in drug development pipelines.
  • Scalability and adaptability: designed to integrate into industrial workflows and support multiple applications, from drug discovery to toxicology and personalized medicine.

A Shared Vision: Science as a Profitable Investment

Beyond the pitch itself, the forum provided an excellent opportunity to engage with potential investors, strategic partners and collaborators who share a long-term vision: investing in science is not only necessary for societal progress but also economically sustainable and profitable.
Events like this reinforce a crucial message for the innovation ecosystem: when science and capital move forward together, transformative impact becomes achievable.

At BFlow, we remain committed to advancing technologies that make biomedical research more predictive, efficient, and human-relevant, while building the partnerships that enable sustainable growth.

We continue building